Article Text
Abstract
Introduction/Background We investigated the feasibility of molecular classification using next-generation sequencing and its relationship with clinical outcomes in patients with endometrial cancer.
Methodology Clinical data and next-generation sequencing data using tumor tissues were retrospectively collected. Next-generation sequencing assays were performed to identify genomic alterations in 323 cancer-related genes.
Results A total of 200 patients with endometrial cancer were classified into four molecular subtype groups: POLEmut group (5%), MSI-H group (23.5%), no specific molecular profile (NSMP) group (48%) and p53abn group (23.5%). The p53abn group showed a greater proportion of non-endometrioid carcinoma (P < 0.001) and advanced-stage cases (P = 0.006). Molecular classification revealed distinct progression-free survival outcomes, with the POLEmut group showing a favorable prognosis, the MSI-H and NSMP groups exhibiting intermediate prognoses, and the p53abn group presenting the least favorable prognosis (P < 0.001). In terms of overall survival, the MSI-H group demonstrated the most favorable prognosis, while the p53abn group showed the least favorable prognosis (P = 0.001). Of the 13 patients (27.7%) in the MSI-H group experiencing recurrence or progression, 6 patients received immunotherapy according to MSI status of NGS results, resulting in 3 complete responses and 3 partial responses.
Conclusion Next-generation sequencing is a useful tool for evaluating clinical outcomes and it can be feasibly used to guide treatment of patients with endometrial cancer.
Disclosures We have no potential conflict of interest to report.